Skip to main content

A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment

Completed · Phase 3 · NCT04083235

Conditions: Metastatic Adenocarcinoma of the Pancreas

At a glance

Research payments reported, 2025
$683,114
U.S. investigators named
46
Sites paid
32
Planned or actual enrollment
770

About the trial

Sponsor
Ipsen
Tested
Irinotecan Liposomal Injection (drug), Oxaliplatin (drug), 5Fluorouracil (drug), Leucovorin (drug), Nab-paclitaxel (drug), Gemcitabine (drug)
Dates
Started 2020-02-11; completion 2025-02-18
Results posted
Yes

The purpose of this study is to look at the efficacy and safety of Irinotecan liposome injection in combination with other approved drugs used for cancer therapy, namely 5 fluorouracil/leucovorin (5FU/LV) plus oxaliplatin compared to nab-paclitaxel + gemcitabine treatment in improving the overall survival of patients not previously treated for metastatic pancreatic cancer.

From ClinicalTrials.gov, last updated 2026-04-20. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Ipsen Bioscience Inc. reported $683,114 in research payments for this study in 2025 (95 payments).

Products named: Onivyde

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.